Latest market price
13.30
+0.47+3.66%
OverviewShort InterestFilings
DRTSQT91Alpha Tau Medical Ltd·NASDAQ
13.30+3.66%
TA
Loading chart...
Screen all →
QURE+0.30%$23.04RARE+2.39%$16.69NUVB+2.35%$4.70TRAX+1.17%$45.58NTLA+3.95%$12.12ABSI+5.42%$10.21URGN-0.50%$34.19MAZE+1.94%$30.96
Snapshot
Index—P/E—EPS (ttm)-1.04Insider Own0.18%Shs Outstand92.48MPerf Week-0.47%
Market Cap1.19BForward P/E—EPS next Y-0.53Insider Trans-81.68%Shs Float64.10MPerf Month-13.13%
Enterprise Value1.10BPEG—EPS next Q-0.14Short Float5.36%Perf Quarter-1.91%
Income-93.00MP/S—EPS this Y—Short Ratio6.30Perf Half Y70.39%
Sales0.00P/B26.97EPS next Y—ROA-68.96%Short Interest3.44MPerf YTD159.19%
Book/sh0.48P/C11.75EPS next 5Y—ROE-138.12%52W High15.79 -15.77%Perf Year217.57%
Cash/sh1.09P/FCF—EPS past 3/5Y—ROIC-40.04%52W Low3.43 287.76%Perf 3Y281.85%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility4.32% 4.42%Perf 5Y29.47%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.63Perf 10Y—
Dividend Ex-Date—Quick Ratio11.09Sales Y/Y TTM—Profit Margin0.00%RSI (14)41.08Recom2.17
Dividend Gr. 3/5Y—Current Ratio11.09EPS Q/Q-284.62%SMA20-4.33%Beta1.26Target Price18.00
Payout0.00%Debt/Eq0.32Sales Q/Q—SMA50-9.76%Rel Volume0.82Prev Close12.83
Employees121LT Debt/Eq0.32EarningsNov 19SMA20020.77%Avg Volume530.74KPrice13.30
IPO DateMar 08, 2021Option/ShortYes / YesEPS/Sales Surpr.-254.91% -30.80%Net Debt/EBITDA—Volume436,732Change3.66%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-03-26ReiteratedBarclaysOverweight$17 → $30
Aug-11-26ReiteratedHC Wainwright & Co.Buy$15 → $16
Jun-04-26ReiteratedBarclaysOverweight$15 → $17
May-28-26ReiteratedBarclays$15
May-19-26ReiteratedPiper SandlerNeutral$7.00 → $8.00
May-12-26ReiteratedHC Wainwright & Co.Buy$12 → $15
Mar-04-26DowngradePiper SandlerOverweight → Neutral
Feb-24-26ReiteratedHC Wainwright & Co.Buy$9.00 → $12
Sep-03-25ReiteratedHC Wainwright & Co.Buy$9.00
May-21-24ReiteratedPiper SandlerOverweight$12 → $7.00
Latest News· Times ET
Oct-29-26
Oct-29-2612:14PM
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchangeglobenewswire.com
Oct-22-26
Oct-22-2608:30AM
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Koreaglobenewswire.com
Oct-19-26
Oct-19-2608:30AM
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meetingglobenewswire.com
04:35AM
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN StudyBenzinga
Oct-05-26
Oct-05-2609:45AM
Alpha Tau to Participate in October Investor Conferencesglobenewswire.com
Sep-11-26
Sep-11-2603:53PM
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And Moreseekingalpha.com
Sep-04-26
Sep-04-2611:56AM
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthroughseekingalpha.com
Sep-03-26
Sep-03-2605:23AM
Barclays Maintains Overweight on Alpha Tau Medical, Raises Price Target to $30Benzinga
Sep-02-26
Sep-02-2608:00AM
Alpha Tau to Participate in September Investor Conferencesglobenewswire.com
Aug-31-26
Aug-31-2608:00AM
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansionsglobenewswire.com
Aug-13-26
Aug-13-2603:33AM
PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrastdefenseworld.net
Aug-11-26
Aug-11-2606:58AM
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16Benzinga
Aug-10-26
Aug-10-2608:00AM
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)globenewswire.com
Jul-22-26
Jul-22-2608:09AM
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price TargetBenzinga
Jul-21-26
Jul-21-2608:30AM
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Successglobenewswire.com
Company

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A0100————
Gross Profit0-100————
Selling, General and Administrative Excl. Other111099————
Research and Development39312726————
Other Operating Expense1001————
Operating Income-51-42-36-36————
Interest Expense
42000————
Unusual Expense
————————
Non-Operating Income (Expense)-1057————
Net Income Before Taxes-93-43-32-29————
Income Taxes
0000————
Consolidated Net Income-93-43-32-29————
Net Income From Continuing Operations-93-43-32-29————
Net Income-93-43-32-29————
EPS (Recurring)-1.04-0.53-0.45-0.42————
EPS (Basic, Before Extraordinaries)-1.04-0.53-0.45-0.42————
EPS (Diluted)-1.04-0.53-0.45-0.42————
EBITDA-49-41-30-28————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding91817069————
Market Capitalization1,210401217208————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$17.34$13.35$9.36$5.36$1.37● Close Price0.00K244.80K489.61K734.41K979.22KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Levy RaphiChief Financial OfficerAug 21 '26Option Exercise2.982,8718,55693,051Aug 25
Levy RaphiChief Financial OfficerAug 21 '26Sale15.002,87143,07390,180Aug 25
Levy RaphiChief Financial OfficerAug 11 '26Option Exercise2.9817,73052,835107,910Aug 12
Levy RaphiChief Financial OfficerAug 11 '26Sale14.0017,730248,27790,180Aug 12
Levy RaphiChief Financial OfficerJul 06 '26Option Exercise2.982,2706,76592,450Jul 07
Levy RaphiChief Financial OfficerJul 06 '26Sale14.002,27031,78290,180Jul 07
Levy RaphiChief Financial OfficerJul 02 '26Option Exercise2.9817,87353,262108,053Jul 06
Levy RaphiChief Financial OfficerJul 02 '26Sale13.0017,873232,39790,180Jul 06
Levy RaphiChief Financial OfficerJul 01 '26Option Exercise2.982,1276,33892,307Jul 02
Levy RaphiChief Financial OfficerJul 01 '26Sale13.022,12727,69190,180Jul 02
Levy RaphiChief Financial OfficerJun 30 '26Sale12.0020,000240,04490,180Jul 01
Levy RaphiChief Financial OfficerJun 25 '26Sale11.0020,000220,004110,180Jun 26
Levy RaphiChief Financial OfficerJun 23 '26Sale9.5517,500167,051130,180Jun 25
Levy RaphiChief Financial OfficerJun 03 '26Sale10.8332,500352,116147,680Jun 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.